Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis

2012 ◽  
Vol 10 (5) ◽  
pp. 343-353 ◽  
Author(s):  
Ronald Vender ◽  
Charles Lynde ◽  
Vincent Ho ◽  
Dina Chau ◽  
Melanie Poulin-Costello
Keyword(s):  
Resource Utilization ◽  
Plaque Psoriasis ◽  
Healthcare Resource ◽  
Work Productivity ◽  
Healthcare Resource Utilization ◽  
Severe Plaque Psoriasis

Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization

2020 ◽  
Vol 24 (6) ◽  
pp. 573-587
Author(s):  
Yves Poulin ◽  
Catherine Beauchemin ◽  
Catherine Royer ◽  
Anne-Julie Gaudreau ◽  
Clarabella Yim ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Real World ◽  
Plaque Psoriasis ◽  
Budget Impact ◽  
Healthcare Resource ◽  
Oral Treatment ◽  
Healthcare Resource Utilization ◽  
Medical Services ◽  
Severe Plaque Psoriasis ◽  
Comorbidity Burden

Background In Québec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral treatment for plaque psoriasis, was added to the Québec provincial health insurance plan (Régie de l’assurance maladie du Québec; RAMQ) formulary in 2015, making this the only province in Canada with public drug plan reimbursement for apremilast. Objectives The aim of this study is to describe patients’ characteristics, treatment patterns, healthcare resource utilization (HCRU), and associated costs and to measure real-world budget impact of using apremilast before biologics in plaque psoriasis. Methods This study was performed using RAMQ drug claims and medical services data. Patients diagnosed with psoriasis between January 2015 and December 2017 were identified. Medical services and prescription claims were categorized as all-cause and psoriasis-related. Using RAMQ database estimates, a 3-year budget impact analysis was developed comparing treatment cost with and without the addition of apremilast to the formulary. Results In all, 540 patients were identified (apremilast: n = 92; biologics: n = 448). Comorbidity burden and treatment persistence and adherence were comparable between apremilast and biologic users. The year following the index date, all-cause HCRU was lower for apremilast versus biologic users (CAN$19 763 vs CAN$28 025; P < .01), mainly driven by drug cost. Using apremilast before biologics resulted in an estimated RAMQ net savings of CAN$49 290 (2015), CAN$746 856 (2016), and CAN$1 216 512 (2017), and a total savings of CAN$2 012 658 since apremilast’s addition to the formulary. Conclusion Adding apremilast to the drug formulary of other Canadian provinces could result in significant healthcare savings.

scholarly journals My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Marja-Liisa Sumelahti ◽  
Markku Sumanen ◽  
Merika S. Sumanen ◽  
Samuli Tuominen ◽  
Johanna Vikkula ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Healthcare Resource ◽  
Negative Impact ◽  
Work Productivity ◽  
Working Life ◽  
Healthcare Resource Utilization ◽  
Categorical Variables ◽  
Emotional Burden ◽  
The Past ◽  
Migraine Frequency

Abstract Background A global My Migraine Voice survey was conducted in 31 countries among 11,266 adults who suffered from ≥4 monthly migraine days (MMD). The aim of this retrospective observational survey-based study was to analyse the country specific results in Finland in order to understand the impact of migraine based on disease severity. Methods The included participants (3%, n = 338/11,266) were stratified by mean MMDs into 4 ≤ MMD < 8 (n = 133), 8 ≤ MMD < 15 (n = 139) and MMD ≥ 15 (n = 66) subgroups. Comorbidities, migraine-related emotional burden and impact on daily living and work productivity and activity impairment (WPAI) were assessed. Subgroup analysis on healthcare resource utilization (HCRU) due to migraine was assessed by visits to healthcare practitioners (HCPs) during the past 6 months and by hospitalizations and emergency room (ER) visits during the past 12 months. The group difference was tested using the one-way ANOVA and for categorical variables using the Chi-squared test. The association between HCRU and MMD and number of comorbidities was assessed using negative binomial regression analysis. Results Mean age was 44 years, 93% were women and 67% (n = 227) were employed. Chronic migraine (CM, MMD ≥ 15) was reported in 19.5% of the respondents. The negative impact on daily functioning and emotional burden increased significantly by migraine frequency. Mean number of comorbidities was 2.4, and mean number of HCP visits during the previous 6 months was 5.9. Increase in migraine frequency and comorbidities was associated with higher HCRU. Eighty-eight percent of the respondents reported negative impact on working life and 52% experienced overall work productivity impairment. Over previous month, the mean number of missed working days for all respondents was 2.8 days of which 54% were paid sick leave days, and in CM up to 6.0 days and 30%, respectively. Both absenteeism and presenteeism were higher in the CM group. Conclusions The emotional and functional burden was high, and the societal burden increased by frequency and severity of migraine, as shown by higher HCRU and reduced work productivity. There is a need to improve quality of care in migraine and improve migraine management related issues in both healthcare and society in Finland.

scholarly journals Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany

2020 ◽  
Vol 9 (12) ◽  
pp. 891-902
Author(s):  
Klaus Krueger ◽  
Sven Remstedt ◽  
Astrid Thiele ◽  
Susanne Hohenberger
Keyword(s):  
Resource Utilization ◽  
Healthcare Resource ◽  
Work Productivity ◽  
Daily Practice ◽  
Healthcare Resource Utilization ◽  
Inflammatory Rheumatic Diseases ◽  
Clinical Settings ◽  
Activity Impairment ◽  
Patient Reported

Aim: To analyze the quality of life (QoL), work productivity and activity impairment (WPAI) and healthcare resource utilization (HCRU) in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients receiving golimumab under routine clinical settings in Germany. Materials & methods: Prospective observational study, GO-ART, analyzed changes in WPAI, QoL and HCRU during 24 months of golimumab therapy. Results: Seven hundred and forty-eight patients (RA = 250, PsA = 249 and AS = 249) were enrolled. Substantial improvements in WPAI scores presenteeism, activity impairment and total work productivity impairment and QoL were observed at month three and were maintained through month 24. Fewer patients had disease-related hospitalizations and consulted physician at month 24 than at the baseline. Conclusion: Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, PsA and AS.

scholarly journals Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers

2021 ◽  
pp. 247553032110217
Author(s):  
Jeffrey M. Sobell ◽  
Ran Gao ◽  
Amanda K. Golembesky ◽  
Nirali Kotowsky ◽  
Elizabeth M. Garry ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Plaque Psoriasis ◽  
Healthcare Resource ◽  
Medication Use ◽  
Healthcare Resource Utilization ◽  
Pustular Psoriasis ◽  
Administrative Claims ◽  
Matched Cohort ◽  
Patient Profile ◽  
Generalized Pustular Psoriasis

Background: Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease with high unmet clinical need. The introduction of a GPP-specific International Classification of Diseases, 10th Revision (ICD-10), code has made it possible to generate a more accurate GPP patient profile. Objectives: To describe the characteristics and compare the patient profile and burden of disease of patients with GPP with patients with plaque psoriasis. Methods: A retrospective study was conducted using a US administrative claims database, the IBM® MarketScan® Research Database. The study took place between October 1, 2015, and September 30, 2018. Patients with at least 1 inpatient or 2 outpatient L40.1 (GPP) or L40.0 (psoriasis vulgaris) diagnostic codes were included for analysis. Outcome measures included descriptions of comorbidities, medication use, and healthcare resource utilization (HCRU) among GPP, plaque psoriasis, and general population (matched to those with GPP) cohorts. Results: Patients with GPP had more baseline comorbidities than those with plaque psoriasis and the matched cohort, including psoriatic arthritis (20.6% vs 6.4% and <0.1%) and hyperlipidemia (20.4% vs 16.3% and 11.8%). Patients with GPP also had greater medication use and higher HCRU than those with plaque psoriasis and the matched cohort. Conclusion: Patients with GPP generally experience more comorbidities, with higher HCRU, than patients with plaque psoriasis. Although the large dataset permitted identification of GPP patients with longitudinal follow-up, the lack of a validation algorithm for GPP is a limitation and a potential area for future research.

scholarly journals Clinical Characteristics and HealthCare Resource Utilization in Patients With Generalized Pustular Psoriasis: Real-World Evidence From a Large Claims-Based Dataset

2021 ◽  
pp. 247553032110217
Author(s):  
Jeffrey Crowley ◽  
Amanda K. Golembesky ◽  
Nirali Kotowsky ◽  
Ran Gao ◽  
Rhonda L. Bohn ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Plaque Psoriasis ◽  
Healthcare Resource ◽  
Burden Of Illness ◽  
Medication Use ◽  
International Classification Of Diseases ◽  
Healthcare Resource Utilization ◽  
Pustular Psoriasis ◽  
Administrative Claims ◽  
Generalized Pustular Psoriasis

Background: Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease with significant unmet clinical need. Historically, GPP has not been well characterized; however, the advent of the International Classification of Diseases, 10th revision, has made it possible to more accurately characterize patients with GPP. Objective: To describe the characteristics and estimate the burden of disease in patients with GPP compared with those with plaque psoriasis. Methods: A retrospective study was conducted using a US administrative claims database, Optum® Clinformatics® Data Mart, between October 1, 2015, and March 31, 2019. Patients with at least 1 inpatient or 2 outpatient diagnosis codes for GPP (L40.1) or psoriasis vulgaris (L40.0) were included. The main outcome measures included the percentage of individuals with comorbidities, medication use, and healthcare resource utilization (HCRU), which were compared between patients with GPP and those with plaque psoriasis and a general population comparator control cohort. Results: Overall, 1,669 patients with GPP were identified at baseline; most patients were female (67.6%). Patients with GPP had more comorbidities than those with plaque psoriasis, specifically metabolic disorders: hyperlipidemia and type 2 diabetes. Medication use for patients with GPP differed from those with plaque psoriasis—patients with GPP required more frequent use of antihypertensives and antibiotics than those with plaque psoriasis. Patients with GPP also had higher HCRU than those with plaque psoriasis. Conclusion: Although this study has limitations, it shows that patients with GPP have a high burden of illness that differs from patients with plaque psoriasis.

Sign in / Sign up

Export Citation Format

Share Document